Abstract 5052: Lowering of the Triglyceride/HDL Cholesterol Ratio Predicts the Benefit of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients
Stephen J. Nicholls(Australian Centre for Heart Health), Steven E. Nissen(Cleveland Clinic), E.Murat Tuzcu, Arman T. Askari, Özgür Bayturan, Stuart Kupfer(Cytokinetics (United States)), V.S. Srinivas(Albert Einstein College of Medicine), Tao Hu(Ministry of Education), Richard W. Nesto(Beth Israel Deaconess Medical Center), Menon, A García-Pérez
Circulation
October 28, 2008
Cited by 4
Related Papers
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
|New England Journal of Medicine|2007|4.7k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k